GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Summary

This is a phase II, multicenter, open-label study to evaluate the antitumor activity, efficacy and safety of GEN-001 in combination with avelumab as a third line (3L) or greater line treatment which is not received the Standard of Care (SOC) for patients with PD-L1 positive advanced GC/Gastroesophageal Junction Adenocarcinoma who are not received cancer immunotherapy regimens as mono or combination therapy.

Timeline

Start

2022-04-07

Primary completion

2024-08-26

Completion

2024-08-26

Drugs

Indications